BEIGENE
Founded in 2010, BeiGene is a global biotechnology company that discovers and develops innovative oncology treatments and aims to make their medicines more accessible and affordable to cancer patients worldwide. The company has more than 9,200 colleagues globally and administrative offices on three continents, as well as one of the largest oncology research teams in the world. BeiGene continues to expand its broad in-house internal clinical development capabilities to make its therapies more av... ailable for patients around the globe. BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, is currently under review by regulators in the U.S. and the EU for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The company’s broad and deep pipeline has the potential to address 80 of cancers by incidence. Adjacent to its product portfolio and pipeline, the company also sponsors programs aimed at serving the broader needs of oncology patients, such as a program to raise awareness of mental health resources for people and families affected by cancer.
BEIGENE
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.beigene.com
Total Employee:
10001+
Status:
Active
Contact:
+1 (877) 828-5568
Email Addresses:
[email protected]
Total Funding:
6.79 B USD
Technology used in webpage:
Domain Not Resolving LetsEncrypt Amazon IPv6 ReCAPTCHA Pound Sterling Apple Mobile Web App Capable ASP.NET IIS Microsoft
Similar Organizations
Avadim Health
Avadim Health is a healthcare and wellness company.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
IgGenix
IgGenix is a biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hillhouse Investment
Hillhouse Investment investment in Post-IPO Equity - BeiGene
Amgen Ventures
Amgen Ventures investment in Post-IPO Equity - BeiGene
GIC
GIC investment in Post-IPO Equity - BeiGene
Amgen
Amgen investment in Post-IPO Equity - BeiGene
Rock Springs Capital
Rock Springs Capital investment in Series B - BeiGene
Hillhouse Investment
Hillhouse Investment investment in Series B - BeiGene
T. Rowe Price
T. Rowe Price investment in Series B - BeiGene
Hillhouse Investment
Hillhouse Investment investment in Series A - BeiGene
CITIC Capital Holdings
CITIC Capital Holdings investment in Series A - BeiGene
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-06-28 | Recorna Bio | BeiGene investment in Seed Round - Recorna Bio | N/A |
| 2023-02-08 | Duo Oncology | BeiGene investment in Seed Round - Duo Oncology | 3 M USD |
| 2021-11-02 | Shoreline Biosciences | BeiGene investment in Series B - Shoreline Biosciences | 140 M USD |
| 2021-06-23 | Strand Therapeutics | BeiGene investment in Series A - Strand Therapeutics | 52 M USD |
| 2021-03-17 | Boston Immune Technologies & Therapeutics | BeiGene investment in Series A - Boston Immune Technologies & Therapeutics | 10 M USD |
| 2020-12-01 | Singlomics | BeiGene investment in Series A - Singlomics | N/A |
| 2020-01-03 | Leap Therapeutics | BeiGene investment in Post-IPO Equity - Leap Therapeutics | 27 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-18 | BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer |
Official Site Inspections
http://www.beigene.com Semrush global rank: 1.25 M Semrush visits lastest month: 22.27 K
- Host name: a1d912ee7c70f87b3.awsglobalaccelerator.com
- IP address: 15.197.152.73
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BeiGene"
Leadership & Board - BeiGene
Xiaodong Wang, Ph.D. is a co-founder of BeiGene and has served as Chairman of our Scientific Advisory Board since 2011. Dr. Wang has been on the Board of Directors since February 2016. Dr. Wang is the founding Director of the …See details»
BeiGene - Wikipedia
BeiGene was founded in late 2010 by John V. Oyler, an American entrepreneur who serves as the company's chief executive officer and chairman, alongside Xiaodong Wang, a Chinese American biochemist. Oyler and Wang envisioned a global multinational biopharmaceutical company focusing on cancer treatment. Xiaodong Wang is former Howard Hughes Medical Investigator at the University of Texas Southwestern Medical Center. The company initially prima…See details»
About Us - Beigene
This is incredibly important as we establish BeiGene in Canada with the goal of bringing patients and clinicians innovative, affordable, and accessible treatments. Our people are truly our most critical asset, and creating a supportive …See details»
Our Mission, Vision & Values - BeiGene
Mission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.. Vision. Transform the …See details»
Who We Are - Beigene
BeiGene Canada is led by a highly experienced and dedicated Canadian team with a shared passion for extending the boundaries of ‘possible’. In close collaboration with global colleagues, we deliver on our promise of bringing …See details»
BeiGene Unveils Proposed Name Change to BeOne Medicines, …
Nov 14, 2024 BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more …See details»
Beigene - Cancer Has No Borders. Neither Do We.
Apr 8, 2021 BeiGene Canada Proud National Sponsor of the Leukemia & Lymphoma Society of Canada’s 2024 Light The Night. May 7, 2024. Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada. Feb 7, 2024. Health …See details»
BeiGene - Crunchbase Company Profile & Funding
BeiGene announced the opening of a new $800M biologics manufacturing and clinical R&D facility in New Jersey, which is expected to create hundreds of jobs. ... BeiGene Foundation: A nonprofit organization providing grants to eliminate …See details»
BeiGene Unveils Proposed Name Change to BeOne Medicines, …
Nov 14, 2024 BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more …See details»
Our Strategy - BeiGene
At BeiGene, our strategy to be a leading corporate citizen relies on providing equitable benefits to our patients, business, and society. Select Your Location: Global; ... an independent 501(c)(3) …See details»
BeiGene - LinkedIn
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, …See details»
BeiGene - The Org
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. …See details»
What We Do - Beigene
BeiGene is focused on creating impactful medicines intended to be accessible to far more patients here in Canada and around the world. We are advancing an innovative, high-value product …See details»
Partnerships - Beigene
LSO is a member-funded, not-for-profit organization advancing Ontario life sciences through advocacy and policy work, educational and networking events, and support services for the life …See details»
BeiGene | Company Overview & News - Forbes
BeiGene Ltd. is a global oncology company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the …See details»
FAQs | BeiGene
BeiGene’s TEVIMBRA, a humanized monoclonal antibody directed against the immune checkpoint receptor PD-1, is approved for the treatment of various solid tumors across the …See details»
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU …
BeiGene: Revenue Growth Projection and Earnings Inflection. As of Q3 2024, BeiGene reported a net loss of $120 million or $0.09/share with total revenue for the quarter of $1.00 billion.See details»
Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada
May 8, 2024 New Office in Canada Signals BeiGene’s Commitment to Innovating Cancer Care for Canadians. Toronto, May 7, 2024 – BeiGene Canada, the country affiliate of global …See details»
Contact Us - BeiGene
Argentina 08002667807. Brazil 08000474711. Chile 800380242. Colombia 18000110575. Mexico 8000622797. Peru 80078025. Uruguay 4135985811See details»